Novo Nordisk will begin US distribution of its Ozempic oral GLP-1 pill on May 4, offering reformulated semaglutide in 1.5mg, 4mg and 9mg strengths. This represents the first oral peptide therapy approved both for glycemic control and for reducing major cardiovascular events in adults with type 2 diabetes at high risk.

Clinical trials demonstrated that the oral Ozempic pill lowers hemoglobin A1c and reduces the risk of heart attack, stroke or cardiovascular death, matching the cardiovascular benefits seen with the injectable form. The pill provides physicians and patients with a choice between injection and oral dosing under a single brand umbrella.

Production of Ozempic tablets is based entirely in the US, with distribution through a network of over 70,000 pharmacies nationwide. Insured patients can access a three-month supply for as little as $25, while out-of-pocket monthly costs for those paying directly range from $149 to $299, depending on dose.

By rebranding Rybelsus strengths into the Ozempic pill, Novo Nordisk aims to simplify treatment recognition and drive brand loyalty. The company has also filed for FDA approval of a 25mg Ozempic tablet, with a regulatory decision expected by the end of 2026.